Re: EGRIFTA- tesamorelin questions- One liner facts from

[Guest guest]

Egrifta is approved as a treatment for abdominal fat accumulation.

Most Medicare part D formularies do not include it yet. Same story with insurance companies and HMOs. The company is working on it.

ADAP patients can get it via patient assistance for free ( max income  60,000 dollars a year without dependents). Doctors have to call AXIS by using the number shown in Egrifta.com

It costs over $2000 a month. 

Injections once a day forever.If you stop, the fat returns

No effect on blood sugar was observed

It can improve bone absorption markers since it increases IGF-1 (like testosterone and anabolics)

It may provide a slight improvement in lean body mass, but the company did not report results from their DEXAs in their studies.  O

Average waist size reduction was only 1.1 inches in studies (not including diet and exercise)

I know some guys in Fort Lauderdale that have had 4-7 inches loss after 14 weeks. All of them started an intensive exercise and low glycemic load diet.

Jeff from this list and I will be meeting the company on April 15 to discuss issues.

On Wed, Apr 6, 2011 at 11:55 AM, Kearns <aidswriteorg@...> wrote:

chers---

so if i am diagnosed with AIDS & osteoporosis and am on social security & medicare & medical & adap, and sally field's osteoporosis medicine is counterindicated for me, 1) is tesamorelin available for PWAs like me on social security? and 2) is tesamorelin safe in patients with AIDS-meds-engendered diabetes? does it also lead to jaw necrosis in pwas with dental problems?

http://www.projectinform.org/news/2011/031511b.shtml

The new HIV-related drug, tesamorelin, may improve bone massFrom CROI, March 2011: In 2010, tesamorelin (Egrifta) was approved by the FDA for

reducing excess gut fat in HIV-positive people. The drug is a human growth hormone releasing factor — a compound that encourages the pituitary gland to secrete growth hormone, which can reduce the visceral fat that lies around internal organs beneath the abdominal muscles. In a 52-week study that led to FDA approval, tesamorelin — which is injected into the stomach once a day — was shown to reduce visceral gut fat by 18%.

 namasté   ---rk

aidswriteorg@...

-- VergelBook link